Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2022

View Archived Issues

Redox-tuned [18F]4FN radiopharmaceutical is useful for imaging innate immunity activation

Evaluating effect of LyeTxI-b on colorectal cancer using chicken chorioallantoic membrane model

Bayer and collaborators patent CSNK1 inhibitors

Foghorn Therapeutics divulges new PROTACs

Jazz Pharmaceuticals synthesizes new Raf kinase inhibitors

Beijing Jacobio Pharmaceuticals presents new glutaminase inhibitors

Chinese investigators identify new PI3Kdelta inhibitors

Osteocytic Cx43 hemichannels as new therapeutic target for treating bone loss and osteoporosis

GI Innovation and CellKey sign biomarker joint research MoU

LABP-66 shows promise for the treatment of multiple sclerosis

VK-1727 reduces EBV proliferation in cells from patients with multiple sclerosis

Lung microbiome affects brain immune cells

Targeting HNRNPA1 effective for treating multiple sclerosis-associated neurodegeneration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...